Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: The present invention is directed to pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: The present invention is directed to heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.

Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.

Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.

Abstract: Systems and methods for a cooling system of a display device are provided herein. One exemplary image display device includes a light source and an image-generation device for receiving light from the light source and generating an image. The image display device also includes a projection lens for projecting the image from the image-generation device. The image display device also includes a body for housing the light source, the image generation device, and the projection lens. The image display device also includes a cooling system coupled to the body. The cooling system may be positionable in a first position and a second position based on a configuration of the body.

Abstract: Pyrazolo-quinazoline derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Abstract: A light integrator for a display device is provided. The light integrator may include a first light tunnel configured to receive a light beam, increase the uniformity of the light distribution in the light beam, and output the light beam, the first light tunnel having a first optical axis. The light integrator may further include a redirection component configured to receive the light beam from the first light tunnel and redirect the light beam to a second light tunnel configured to further increase the uniformity of the light distribution in the light beam and transmit the light beam to downstream optical components, the second light tunnel having a second optical axis forming an angle less than 180 degrees and non-perpendicular with the first optical axis.

Abstract: Systems and methods for a cooling system of a display device are provided herein. One exemplary image display device includes a light source and an image-generation device for receiving light from the light source and generating an image. The image display device also includes a projection lens for projecting the image from the image-generation device. The image display device also includes a body for housing the light source, the image generation device, and the projection lens. The image display device also includes a cooling system coupled to the body. The cooling system may be positionable in a first position and a second position based on a configuration of the body.

Abstract: MVS mainframe computer systems employ the ICF (Integrated Catalog Facility) catalog environment to manage numerous data sets. To provide nearly continuous availability of those data sets, the BCS catalog (250,270) must be re-organized while leaving the catalog open to access by applications. To perform a re-org while open, a data CI correlation table (500) can be constructed (314) and used to lay the data CIs into a backup file in logical order (316), so that they can be loaded into the new BCS catalog (324) without sorting, thereby reducing downtime.

Abstract: One embodiment of the current LED therapy device comprises at least a left and right LED panel, each panel having a front surface and a back surface, the front surface of the left panel forming an angle relative to the front surface of the right panel of 70° to 170°. Each panel's front surface is generally vertically oriented. The embodiment also includes a detachably coupled pedestal. The pedestal includes a panel attachment section, a stem section, and a base section. The panel attachment section is detachably coupled to the left and right LED panels through a v-shaped slot and flange coupling. The panel attachment section is detachably coupled to the stem section, which, in turn, is also detachably coupled to the base section.

Abstract: MVS mainframe computer systems employ the ICF (Integrated Catalog Facility) catalog environment to manage numerous data sets. To provide 24×7 availability of those data sets, the BCS (250,270) must be re-organized while leaving the catalog open to access by applications. To perform a re-org while open, a data CI correlation table (500) is constructed (314) and used to lay the data CIs into a backup file in logical order (316), so that they can be loaded into the new BCS (324) without sorting, thereby reducing downtime. Additionally, if the BCS is damaged during normal operation, repair of the structure must also be performed to ensure that correct access is maintained to all data that is cataloged in the BCS. Throughout the re-org process, structural integrity checks are performed on the data and index component of the BCS, and if errors are encountered, they can be repaired.

Abstract: The invention relates to a method of producing containers such as envelope wallets and folders or the like, which comprise at least two outer wall components (4,6) margins of which are bonded on three sides of the wall components to edges of a flexible extruded plastics material strip (12) which in the example given is polyvinyl chloride, and which has a V-cross-section or a W-cross-section and forms an insertor gusset. The container may have at least one interior wall component provided with adjacent inserts (12) bonded to neighboring wall components. Dielectric heating may be used for the bonding step and suitable apparatus is also described.